sFlt-1
Device
Brahms GmbH
Total Payments
$58,039
Transactions
52
Doctors
0
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $183.33 | 8 | 0 |
| 2023 | $166.25 | 11 | 0 |
| 2022 | $231.70 | 11 | 0 |
| 2021 | $190.99 | 10 | 0 |
| 2020 | $114.78 | 6 | 0 |
| 2019 | $94.56 | 5 | 0 |
| 2018 | $57,057 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $58,039 | 52 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Identification and validation of a cut-off for ration soluble Fms-like Tyrosine Kinase-1 to placental growth factor to stratify rist in pregnat women with hypertensive disorders | Brahms GmbH | $57,057 | 0 |
| Identification and validation of a cut-off for the ratio of suluble Fms-like Tyrosine Kinase-1 to Placental Growth Factor (sFlt-1/PlGF) to Stratify Risk in Pregnant Women with Hypertensive Disorders of Pregnancy - PRAECIS | Fisher Scientific Company L.L.C. | $887.05 | 0 |
| Identification and validation of a cut-off for the ratio of suluble Fms-like Tyrosine Kinase-1 to Placental Growth Factor (sFlt-1/PlGF) to Stratify Risk in PRAECIS | Fisher Scientific Company L.L.C. | $94.56 | 0 |
Top Doctors Receiving Payments for sFlt-1
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Los Angeles, CA | $58,039 | 52 |
Ad
Manufacturing Companies
- Brahms GmbH $57,057
- Fisher Scientific Company L.L.C. $981.61
Product Information
- Type Device
- Total Payments $58,039
- Total Doctors 0
- Transactions 52
About sFlt-1
sFlt-1 is a device associated with $58,039 in payments to 0 healthcare providers, recorded across 52 transactions in the CMS Open Payments database. The primary manufacturer is Brahms GmbH.
Payment data is available from 2018 to 2024. In 2024, $183.33 was paid across 8 transactions to 0 doctors.
The most common payment nature for sFlt-1 is "Unspecified" ($58,039, 100.0% of total).
sFlt-1 is associated with 3 research studies, including "Identification and validation of a cut-off for ration soluble Fms-like Tyrosine Kinase-1 to placental growth factor to stratify rist in pregnat women with hypertensive disorders" ($57,057).